Congestive Heart Failure (CHF) Treatment Devices Market Intelligence with Growing Opportunities During the Forecast Period

Global Congestive Heart Failure (CHF) Treatment Devices Market would reach $14.8 billion by 2022, at a CAGR of 5.5% from 2016 to 2022, according to a new report published by Allied Market Research.Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate the global CHF treatment devices market throughout the forecast period. North America is projected to continue its lead in terms of revenue, accounting for more than two-fifths share of the CHF treatment devices.

The major factors boosting the market growth include the growing incidence of heart failures, technological advancements in CHF treatment devices, and increasing adoption rates for these devices. In addition, rising incidence of diabetes, atherosclerosis, strokes, hypertension, and others due to faulty lifestyle habits such as unhealthy dietary habits, lack of physical activity, and smoking, among others are the leading causes of congestive heart failure.

Rising geriatric population base is expected to fuel the prevalence of congestive heart failures thereby augmenting the market growth. Presence of huge unmet medical needs and rising emphasis on early intervention and primary prevention of heart failures are also anticipated to drive the demand for these devices. However, high cost of these devices and unfavorable reimbursement scenario in the emerging countries are some of the factors that restrict the market growth.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/663

The key players profiled include
• Abiomed, Inc.,
• Berlin Heart GmbH,
• Biotronik SE & Co. KG,
• Boston Scientific
• Corporation,
• HeartWare International, Inc.,
• Jarvik Heart, Inc.,
• LivaNova PLC,
• Medtronic plc,
• ReliantHeart Inc.
• St. Jude Medical, Inc

Geographically, North America accounted for the majority of the share in the CHF treatment devices market in 2015, and is expected to maintain this lead throughout the forecast period. This was mainly attributed to the increasing incidence of heart failures, presence of highly sophisticated healthcare infrastructure, and adoption of advanced CHF treatment devices in the North American countries. However, Asia-Pacific is expected to be the fastest growing region throughout the analysis period, owing to ample growth opportunities in terms of unmet medical needs for the treatment of cardiac disorders in these regions.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/663

Key Findings of the CHF Market:

• In 2015, ICDs accounted for almost one-third of the overall market revenue, and is projected to grow at a CAGR of 4.8% during the forecast period.
• The VADs segment is likely to grow at a remarkable CAGR of 11.9%, owing to the innovation and miniaturization of devices.
• North America accounted for over 40% share of the global CHF treatment devices market in 2015.
• The U.S. is projected to maintain its lead in the CHF treatment devices market until 2022.
• China and Japan are the major shareholders in the Asia-Pacific region, jointly accounting for almost half of share in the Asia-Pacific market.

For More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/663

Table of Content

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.5.1 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2027 ($Million)

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis

3.3.1 High competition and fragmented market moderates the power of the suppliers
3.3.2 Scattered and large number of buyers moderates their bargaining power
3.3.3 High capital investment moderates the threat of new entrants
3.3.4 High intensity of rivalry
3.3.5 Unavailability of substitutes lowers the threat of substitutes

3.4 Market share analysis, 2015
3.5 Market dynamics

3.5.1 Drivers

3.5.1.1 Growing incidences of congestive heart failures
3.5.1.2 Technological advancements in CHF treatment devices
3.5.1.3 Increasing patient awareness
3.5.1.4 Presence of high-unmet medical needs

3.5.2 Restraints

3.5.2.1 Limited insurance coverage and high cost of the CHF treatment devices
3.5.2.2 unfavorable preference to pharmaceutical interventions (drugs) over CHF treatment devices

3.5.3 Opportunities

3.5.3.1 Lucrative opportunities in emerging economies
3.5.3.2 Development of new MRI-labeled devices

Access Full Summery @ https://www.alliedmarketresearch.com/congestive-heart-failure-treatment-devices-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.